Navigate the Astex Pharma ASTX Research Pages
- Introduction (background, summary, links, valuation, financials, outlook, upcoming catalysts)
- Supergen-Astex merger (details on transformative transaction in 2011)
- DACOGEN (aka decitabine, marketed product for myelodysplastic syndrome MDS by Eisai and JNJ)
- AT13387 (HSP90 inhibitor for cancer)
- SGI-110 (follow-on to Dacogen for MDS and AML)
- Amuvatinib (aka MP470 in development for small-cell lung cancer SCLC)
- AT7519 (CDK inhibitor for multiple myeloma)
- Fragment-based Drug Discovery Collaborations (via Astex Ltd side of merger)
- Pipeline (other assets in development)
- Montigen (proposed spin-out transaction info and assets)
Amuvatinib (aka MP-470)
- Oral multitargeted TKI and Rad51 DNA repair suppressor-synergy w/ chemo
- IND 3/2007; >125 pts txd, single agent p1 and p1b combo w/ chemo
- data 8/09 in SCLC and neuroendocrine tumors w/ good efficacy signals (10/11 SD or shrinkage), no overlapping side effects or CYP activity)
- 8/2010: p1 analysis complete, data present ASCO 2011, will help partnering and plan p2 (could do small randomized on own if not partner first) w/ newly devel lipid formulation (better PK results-inc bioavailability)
- 10/2010: start small, focused p2 POC late10 or early 11 (slip) in Pt-refractory SCLC (combo with carbo/etop) or maybe neuroendocrine or both then partner
- 2010 10k: "four issued patents and eight patent applications, having projected expiration dates ranging from October 14, 2024 to March 1, 2027, granted or pending in the jurisdictions of the U.S., the European Patent Office ("EPO"), Australia and Canada."